Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

Following CARMENA and SURTIME, patients with metastatic renal cell carcinoma (mRCC) and International Metastatic RCC Database Consortium (IMDC) intermediate and poor risk receive systemic therapy with the primary tumour (primary) in place, with the option of deferred cytoreductive nephrectomy (CN) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Meerveld-Eggink, Aafke, Graafland, Niels, Wilgenhof, Sofie, Van Thienen, Johannes V., Lalezari, Ferry, Grant, Michael, Szabados, Bernadett, Abu-Ghanem, Yasmin, Kuusk, Teele, Boleti, Ekaterini, Blank, Christian U., Haanen, John B.A.G., Powles, Thomas, Bex, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738899/
https://www.ncbi.nlm.nih.gov/pubmed/35024632
http://dx.doi.org/10.1016/j.euros.2021.11.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738899/
https://www.ncbi.nlm.nih.gov/pubmed/35024632
http://dx.doi.org/10.1016/j.euros.2021.11.003

Ejemplares similares